Company profile for Imugene

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Our product pipeline includes oncolytic viruses (subject to share holders approval at the EGM) and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. We are...
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Our product pipeline includes oncolytic viruses (subject to share holders approval at the EGM) and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
37 Bligh Street Suite 1006, Level 10 Sydney, NSW, 2000 Australia
Telephone
Telephone
61.3.9824.5254
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/imugene-and-jw-therapeutics-announce-a-collaboration-to-advance-oncarlytics-and-carteyva-combination-in-solid-tumours-302627893.html

PR NEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2024/09/03/2939702/0/en/Three-Complete-Responses-in-Azer-Cel-Allogeneic-CD19-CAR-T-Phase-1b-Trial-in-Blood-Cancer-Diffuse-Large-B-Cell-Lymphoma.html

GLOBENEWSWIRE
03 Sep 2024

https://www.fiercepharma.com/manufacturing/cdmo-kincell-inks-car-t-supply-pact-imugene-pays-6m-its-north-carolina-manufacturing

FIERCE PHARMA
17 Apr 2024

https://www.globenewswire.com/news-release/2024/04/16/2863459/0/en/Imugene-and-Kincell-Bio-Announce-Strategic-Manufacturing-and-Process-Development-Partnership.html

GLOBENEWSWIRE
16 Apr 2024

https://www.globenewswire.com/news-release/2024/04/15/2863161/0/en/Bile-Tract-Cancer-expansion-study-opens-following-clearance-of-Imugene-s-MAST-trial-high-dose-cohort.html

GLOBENEWSWIRE
15 Apr 2024

https://www.globenewswire.com/news-release/2024/04/09/2860250/0/en/Imugene-s-oncolytic-virotherapy-VAXINIA-and-B-cell-immunotherapy-HER-Vaxx-featured-at-the-AACR-Annual-Meeting-2024.html

GLOBENEWSWIRE
09 Apr 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty